Five patents currently held, every record listed here
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2037. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2037
Next term end
5
Patent families
When these terms end
Each bar runs from grant to computed term end. 2015 to 2042.20212027203320392042
2 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2039 · High confidence
Also notable
Ends Aug 2038 · High confidence
Also notable
Ends Dec 2037 · High confidence
Method for Observing Sebaceous Gland and Use Thereof
US 11,047,849
The newest of the three, granted 2021. It anchors the portfolio to 2039, later than anything else here.
Immortalized Sweat Gland Myoepithelial Cell
US 11,060,061
The newest of the three, granted 2021. It anchors the portfolio to 2038, later than anything else here.
Method for Observing Dynamics of Sweat Glands
US 11,085,916
The newest of the three, granted 2021. It anchors the portfolio to 2037, later than anything else here.
Formerly held, still cited
Notable
Ends Sep 2027 · High confidence
Renewed at every maintenance window since the 2015 grant; no more fees are due before its term ends in 2027.
now held by Regenetiss Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Method for Detecting Indicator of Immune-Related Disease | 1 in force | to Feb 2042 |
| Method for Observing Sebaceous Gland and Use Thereof | 1 in force | to Sep 2039 |
| TRPA1 Activity Inhibitor | 1 in force | to Sep 2038 |
| Immortalized Sweat Gland Myoepithelial Cell | 1 in force | to Aug 2038 |
| Method for Observing Dynamics of Sweat Glands | 1 in force | to Dec 2037 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,085,916 | Method for Observing Dynamics of Sweat Glands held by Mandom Corporation and Osaka University In force · High confidence | In force | High confidence | |
| US 11,060,061 | Immortalized Sweat Gland Myoepithelial Cell held by Mandom Corporation and Osaka University In force · High confidence | In force | High confidence | |
| US 11,464,720 | TRPA1 Activity Inhibitor held by Mandom Corporation and Takasago International Corporation In force · High confidence | In force | High confidence | |
| US 11,047,849 | Method for Observing Sebaceous Gland and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,306,171 | Method for Detecting Indicator of Immune-Related Disease held by Mandom Corporation, Osaka University and National Institutes of Biomedical Innovation, Health and Nutrition In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 1 patent in force now held by others · 6 patents ended · 2 applications pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.